𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A randomized clinical trial comparing concurrent and alternating thoracic irradiation for patients with limited small cell lung carcinoma

✍ Scribed by Bernard Lebeau; Thierry Urban; Jeanne-Marie Bréchot; Dominique Paillotin; Jean Vincent; Pascal Leclerc; Paul Meekel; Pierre L'Her; François-Xavier Lebas; Claude Chastang; for the “Petites Cellules” Group

Publisher
John Wiley and Sons
Year
1999
Tongue
English
Weight
116 KB
Volume
86
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis

BACKGROUND.

Although thoracic radiotherapy is considered to be useful for the treatment of patients with small cell lung carcinoma (SCLC), its optimal administration schedule is still controversial.

METHODS.

In a multicenter clinical trial, 164 patients with limited SCLC (of whom 156 were eligible for the study) were randomized to receive either concurrent thoracic irradiation, initiated immediately after the second cycle of chemotherapy (Days 30 -64) at a dose of 50 grays in 20 fractions, or alternating thoracic irradiation, scheduled in 3 courses between the second, third, fourth, and fifth cycles of chemotherapy with a 7-day rest period after and before chemotherapy at a dose of 20 grays in 8 fractions (Days 36 -47 and Days 64 -75) and then 15 grays in 6 fractions (Days 92-101). The same chemotherapy regimen (cyclophosphamidedoxorubicin or vindesine-etoposide) was administered every 4 weeks in both groups.

📜 SIMILAR VOLUMES

Carboplatin, etoposide, and accelerated
Carboplatin, etoposide, and accelerated hyperfractionated radiotherapy for elderly patients with limited small cell lung carcinoma : A phase II study
✍ Branislav Jeremic; Yuta Shibamoto; Ljubisa Acimovic; Slobodan Milisavljevic 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 173 KB 👁 2 views

## Background: It is not clear how well elderly patients with limited small cell lung carcinoma tolerate intensive chemotherapy, and they have often been treated with palliative intent. as an alternative strategy, the authors designed and employed a short term combination regimen consisting of carb

A phase I/II trial of neoadjuvant chemot
A phase I/II trial of neoadjuvant chemotherapy with cisplatin and vinorelbine followed by accelerated irradiation for patients with inoperable nonsmall cell lung carcinoma
✍ Jean Viallet; Marc-André Brassard; Luis Souhami; Joseph Ayoub; Pierre Del Vecchi 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 108 KB 👁 2 views

## BACKGROUND. Both locoregional and distant disease control remains poor in the treatment of Stage III nonsmall cell lung carcinoma (NSCLC). This trial was conducted to evaluate the tolerance and responses of patients with NSCLC given a neoadjuvant regimen of cisplatin and vinorelbine chemotherapy

Mature results of a Phase III randomized
Mature results of a Phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with Stage III and IV squamous cell carcinoma of the head and neck
✍ David J. Adelstein; Pierre Lavertu; Jerrold P. Saxton; Michelle Secic; Benjamin 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 102 KB 👁 2 views

The current study presents mature results from a Phase III randomized trial comparing radiation therapy and concurrent chemoradiotherapy in patients with resectable American Joint Committee on Cancer Stage III and IV disease.

Induction chemotherapy employing dose-in
Induction chemotherapy employing dose-intense cisplatin with mitomycin and vinblastine (MVP400), followed by thoracic surgery or irradiation, for patients with stage III nonsmall cell lung carcinoma
✍ Kenneth K. Ng; Mark G. Kris; Robert J. Ginsberg; Robert T. Heelan; Katherine M. 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB 👁 2 views

## BACKGROUND. Cisplatin-based induction chemotherapy before surgery or irradiation has improved the survival of patients with Stage III nonsmall cell lung carcinoma (NSCLC). Encouraged by earlier results with preoperative MVP (cisplatin [120 mg/m 2 or 25 mg/m 2 /week], vinblastine, and mitomycin)

A randomized trial of hybrid administrat
A randomized trial of hybrid administration of cyclophosphamide, doxorubicin, and vincristine (CAV)/Cisplatin and etoposide (PVP) versus sequential administration of CAV-PVP for the treatment of patients with small cell lung carcinoma : Results of long term follow-up
✍ Hiroshi Ueoka; Katsuyuki Kiura; Masahiro Tabata; Haruhito Kamei; Kenichi Gemba; 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 101 KB 👁 2 views

## BACKGROUND. In an attempt to determine the efficacy of cyclophosphamide, doxorubicin, and vincristine (CAV)/cisplatin and etoposide (PVP) hybrid chemotherapy (HYB), a rapidly alternating chemotherapy, in patients with small cell lung carcinoma (SCLC), the authors conducted a randomized study to